Gilead Non Current Liabilities Total from 2010 to 2024
| GILD Stock | USD 90.19 0.43 0.48% |
Non Current Liabilities Total | First Reported 1991-03-31 | Previous Quarter 24.6 B | Current Value 24.4 B | Quarterly Volatility 13.3 B |
Check Gilead Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gilead Sciences' main balance sheet or income statement drivers, such as Interest Expense of 534.5 M, Total Revenue of 28.5 B or Gross Profit of 28.5 B, as well as many indicators such as Price To Sales Ratio of 3.54, Dividend Yield of 0.0268 or PTB Ratio of 7.87. Gilead financial statements analysis is a perfect complement when working with Gilead Sciences Valuation or Volatility modules.
Gilead | Non Current Liabilities Total |
Latest Gilead Sciences' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Gilead Sciences over the last few years. It is Gilead Sciences' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gilead Sciences' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Gilead Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 23,034,266,667 | |
| Geometric Mean | 10,210,307,232 | |
| Coefficient Of Variation | 56.10 | |
| Mean Deviation | 10,983,520,000 | |
| Median | 28,395,000,000 | |
| Standard Deviation | 12,921,799,346 | |
| Sample Variance | 166972898.3T | |
| Range | 38.8B | |
| R-Value | 0.82 | |
| Mean Square Error | 60117494.1T | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | 2,357,429,861 | |
| Total Sum of Squares | 2337620576.6T |
Gilead Non Current Liabilities Total History
About Gilead Sciences Financial Statements
Gilead Sciences stakeholders use historical fundamental indicators, such as Gilead Sciences' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Gilead Sciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gilead Sciences' assets and liabilities are reflected in the revenues and expenses on Gilead Sciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gilead Sciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 28.1 B | 29.5 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out the analysis of Gilead Sciences Correlation against competitors. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 3.06 | Earnings Share 0.09 | Revenue Per Share 22.703 | Quarterly Revenue Growth 0.07 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.